Feb. 3 at 5:13 PM
$EBS The plot thickens:
BARDA finally pulled the trigger on funding a BioMap Consortium project to bring the "Vero" cells manufacturing back to the US. Total program obligation is
$300M, managed by ATI.
Should we win that 'stalking horse' bid for Alachua's Vero cell royalty stream, we'll own that IP which, in turn, would position us well to get a
$20-
$30M incremental revenues from BioMap.
We would save costs on ACAM2000, and even generate some extra 'juice' from a pool of funds we did not tap into before.
